Press Room

News / Oct 13, 2023

ɫAV shortlisted for the CPhI Pharma Awards 2023!

ɫAV shortlisted for the CPhI Pharma Awards 2023!

ɫAV_CPhI Pharma Awards 2023

ɫAV is once again shortlisted for the prestigious CPhI Pharma Awards 2023!

iSDX – a fully automated, scale representative laboratorial and spray dryer – was nominated in the category of Manufacturing Excellence.

iSDX was designed by ɫAV with the aim of developing processes, establishing design spaces, anticipating challenges and producing material representative of commercial scale dryers using a compact lab unit. This is achieved by mimicking the conditions of large dryers in small scale. This dryer was engineered by ɫAV using modelling and simulation tools and is routinely used for process development and troubleshooting.

Coupling iSDX withASD-HIPROS in an integrated offer enables our customers to extensively study and optimize their amorphous solid dispersion formulations while also generating scale representative material for drug product development.

We are thrilled by this nomination which acknowledges our commitment to innovation in pharma and to delivering best-in-class technologies to our customers.

ɫAV has the largest number of Spray Drying commercial projects.

ISDx2_ɫAV

Also in the Press Room

See All

Lisbon, Portugal – ɫAV, the specialist integrated pharma CDMO and leader in spray drying and particle engineering, today announced its commitment to setting Science-Based Targets (SBTs) in line with the Paris Agreement. This ambitious step underscores the company’s dedication to addressing climate change and driving sustainability across its operations. By committing to SBTs, ɫAV joins a growing number of businesses taking concrete actions to reduce greenhouse gas emissions. This initiative aligns with the company’s broader sustainability strategy and reinforces its commitment to scientific excellence. “At ɫAV, we believe in science and in best practices. And this clearly applies to our sustainability agenda.”, said Jean-Luc Herbeaux, CEO of ɫAV. We made the decision to drive our GHG emissions down using a science-based target setting process, which will help us drive sustainability across our operations by laying out a clearly defined path to reduce emissions in line with the Paris Agreement goals. We believe that by setting ambitious targets and implementing concrete actions, we can make a positive impact on the planet while driving innovation and growth.” ɫAV will work closely with the Science Based Targets initiative (SBTi) to develop and validate its emission reduction targets. The company will provide regular updates on its progress towards achieving these goals. As part of its commitment to sustainability and transparency to stakeholders, the company will enhance its Ecovadis rating. Ecovadis, a leading sustainability assessment platform in the pharmaceutical industry, provides a comprehensive evaluation of a company’s environmental, social, and ethical performance, well aligned with ɫAV’s sustainability ambitions.  ɫAV remains dedicated to operating responsibly and contributing positively to society and the environment. The company will continue to implement sustainable practices across its operations and innovate to further improve its sustainability rating.   Learn more about Science Based-Targets  

News

ɫAV Commits to Science-Based Targets for Greenhouse Gas (GHG) Emissions

Sep 09, 2024